+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-12-24Number of Pages: 85

High Potency Active Pharmaceutical Ingredient (HPAPI) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

Development of Targeted Therapeutic Drugs Drives Global HPAPI Market

The booming oncology research and rising cases of cancer, diabetes, and other cardiovascular diseases have created a sizeable demand for dedicated treatments, thereby driving the high potency active pharmaceutical ingredient (HPAPI) market. The HPAPI market stood at a valuation of US$2.64 bn in 2014. The cost containment strategies adopted by companies through outsourcing are favoring market growth. This has brought down the cost of drugs drastically, making them affordable to a larger audience. The positive result of this trend is seen on the increased focus of companies on drug development and commercialization. As a result of these favorable trends, the HPAPI market is projected to be worth US$25.11 bn by 2023. Between 2015 and 2023, the market is expected to expand at a CAGR of 8.3%. 

A promising pipeline of targeted therapeutic drugs will also help the market progress in the coming years. These drugs have minimal side effects and impact targeted areas, thereby helping the patient to recover faster with no lingering after effects. These positive perceptions surrounding HPAPIs combined with the near-expiration dates of blockbuster drugs, which will offer several generic drug manufacturers a chance to offer affordable drugs, will further the market’s growth. Consistent research and development to mimic branded drugs will create alternative and cost-effective treatments for patients across the globe, thereby augmenting the growth rate of the market.

Emerging Nations in Asia Pacific Becoming Hubs of Generic Drug Manufacturing, to Aid HPAPI Market Growth

Asia Pacific is the expected to be the most lucrative market for high potency active pharmaceutical ingredients due to the soaring contract manufacturing activities in the region. Analysts predict that China will surpass Japan’s current share of 40% in the Asia Pacific market by the end of 2025. This change will be a result of low labor costs in China, well-equipped manufacturing plants, and supportive foreign exchange policies.

India will also be an upcoming high potency active pharmaceutical ingredients market due to the growing concentration of pharmaceutical manufacturing activities in the country. In the forecast period, the country is expected to be the hub for generic drug manufacturing. The growing investments by key players in India are also anticipated to boost this market in the near future. During the forecast period of 2015 to 2023, the Asia Pacific HPAPI market is expected to rise at a CAGR of 10.1%.

Oncology Drugs Show Maximum Demand

The oncology drugs segment has been the leading segment of the global high potency active pharmaceutical ingredient market. This segment is expected to expand at CAGR of 8.3% during the forecast period. The introduction of innovative drugs is the primary growth driver for the oncology segment. Analysts predict that the patent expiry of blockbuster drugs such as Herceptin, Rituxan, and Humira will pave the way for generic drug manufacturers, thereby making these drugs affordable to a wide number of patients.

Some of the leading players operating in the global high potency active pharmaceutical ingredient market are WuXi AppTec, Sigma-Aldrich Co. LLC, Pfizer, Inc., Sandoz International GmbH, Novasep, Lonza Group, Dr. Reddy's Laboratories, Cambrex Corporation, and Alkermes plc. The fragmented nature of this market will result in strategies to acquire and merge with regional players to gain the first-mover advantage.


Chapter 1 Introduction  
1.1 Report Description  
1.2 Market Segmentation 
1.3 Research Methodology  
1.4 Assumptions

Chapter 2 Executive Summary  
2.1 Market Snapshot: Global HPAPI Market 
2.2 Comparative Analysis: HPAPI Market, by Geography, 2014 & 2023 
2.3 Waterfall Chart: Global HPAPI Market, by Product, 2014 (US$ Mn) 

Chapter 3 Global HPAPI Market Overview  
3.1 Market Definition and Overview 
3.2 Regulatory Landscape 
3.3 HPAPI Manufacturing Capabilities of Major HPAPI CMOs 
3.2 Market Dynamics 
      3.2.1 Drivers  
      3.2.2 Restraints 
      3.2.3 Opportunities 
3.3 Porter’s Five Forces Analysis: Global HPAPI Market 
3.5 Event Impact analysis  
3.6 Value Chain Analysis
3.7 Market Attractiveness Analysis  
3.8 Market Share Analysis 

Chapter 4 Global HPAPI Market, by Type of HPAPI, 2013 – 2023 (US$ Mn)  
4.1 Synthetic HPAPI Market Revenue, 2013 – 2023 (US$ Mn) 
4.2 Biological HPAPI Market Revenue, 2013 – 2023 (US$ Mn)

Chapter 5 Global HPAPI Market, by Type of Manufacturer, 2013 – 2023 (US$ Mn) 
5.1 Captive or In-house HPAPI Market Revenue, 2013 – 2023 (US$ Mn)
5.2 Contract or Third Party HPAPI Market Revenue, 2013 – 2023 (US$ Mn) 

Chapter 6 Global HPAPI Market, by Type of Drug, 2013 – 2023 (US$ Mn) 
6.1 Branded HPAPI Market Revenue, 2013 – 2023 (US$ Mn)
6.2 Generic HPAPI Market Revenue, 2013 – 2023 (US$ Mn)

Chapter 7 Global HPAPI Market, by Therapeutic Area, 2013 – 2023 (US$ Mn) 
7.1 Oncology Drugs Market Revenue, 2013 – 2023 (US$ Mn)
7.2 Anti-diabetic Drugs Market Revenue, 2013 – 2023 (US$ Mn)
7.3 Cardiovascular Drugs Market Revenue, 2013 – 2023 (US$ Mn)
7.4 Central Nervous System Drugs Market Revenue, 2013 – 2023 (US$ Mn)
7.5 Musculoskeletal Drugs Market Revenue, 2013 – 2023 (US$ Mn)
7.6 Other Drugs Market Revenue, 2013 – 2023 (US$ Mn)

Chapter 8 Global HPAPI Market, by Geography, 2013 – 2023 (US$ Mn) 
8.1 Introduction  
8.2 North America  
      8.2.1 U.S. Market Revenue, 2013 – 2023 (US$ Mn) 
      8.2.2 Canada Market Revenue, 2013 – 2023 (US$ Mn) 
8.3 Europe 
      8.3.1 U.K. Market Revenue, 2013 – 2023 (US$ Mn)
      8.3.2 Germany Market Revenue, 2013 – 2023 (US$ Mn)
      8.3.3 Rest of Europe Market Revenue, 2013 – 2023 (US$ Mn) 
8.4 Asia Pacific  
      8.4.1 Japan Market Revenue, 2013 – 2023 (US$ Mn) 
      8.4.2 China Market Revenue, 2013 – 2023 (US$ Mn) 
      8.4.3 Rest of Asia Pacific Market Revenue, 2013 – 2023 (US$ Mn) 
8.5 Latin America 
      8.5.1 Brazil Market Revenue, 2013 – 2023 (US$ Mn) 
      8.5.2 Rest of Latin America Market Revenue, 2013 – 2023 (US$ Mn) 
8.6 Middle East & Africa 
      8.6.1 GCC Countries Market Revenue, 2013 – 2023 (US$ Mn) 
      8.6.2 Rest of Middle East and Africa Market Revenue, 2013 – 2023 (US$ Mn) 

Chapter 9 Recommendations  

Chapter 10 Company Profiles  
10.1 Alkermes plc 
10.2 Cambrex Corporation  
10.3 Dr. Reddy's Laboratories  
10.4 Lonza Group  
10.5 Novasep  
10.6 Sandoz International GmbH 
10.7 Pfizer, Inc. 
10.8 Sigma-Aldrich Co. LLC. 
10.9 WuXi AppTec

Global high potency active pharmaceutical ingredient (HPAPI) market report provides comprehensive analysis considering various macro as well as micro economic factors. The report studies the HPAPI market from five perspectives: type of HPAPI, type of manufacturer, type of drug, therapeutic area, and geography.

The global high potency active pharmaceutical ingredient market report provides insights on contract versus captive HPAPI, synthetic versus biological HPAPI, and branded versus generic HPAPI. The global high potency active pharmaceutical ingredient market is also segmented into major therapeutic areas which include oncology, anti-diabetic, cardiovascular, central nervous system, musculoskeletal and others. From geography perspective, the market is studied for five main geographies: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America HPAPI market is sub-segmented for the U.S., Canada, while Europe HPAPI market is further segmented for Germany, U.K., and Rest of Europe. Asia Pacific HPAPI market is segmented for Japan, China and Rest of Asia Pacific. Latin America market is segmented for Brazil and Rest of Latin America. Middle East and Africa HPAPI market segmented for GCC Countries and Rest of Middle East and Africa.

Market size for each of the aforementioned segments and sub-segments is provided in US$ Mn considering 2013 and 2014 as base years and forecast from 2015 to 2023. The forecast model considers various factors such as drug patent expiry, therapeutic indication, prevalence, generic competition, anticipated drug approvals, impact of regulatory policies, industry pricing strategies and others. The research methodology is a blend of primary as well as secondary market research, where market estimates based on desk research are further refined considering inputs from expert interviews.

The global high potency active pharmaceutical ingredient market report also provides qualitative information on HPAPI manufacturing capabilities of major players in the market. The report also includes details on current regulatory policies. Major factors driving and restraining the global HPAPI market are also discussed in the report, while lucrative opportunities from future perspective are also mentioned. Furthermore, the global high potency active pharmaceutical ingredient market report also provides event impact analysis, which maps key events impacting market growth including facility expansion, mergers and acquisitions, changes in regulatory policies, drug approval, drug patent expiry and generic or biosimilars drug approval. Value chain analysis is also provided for comprehensive analysis. Porter’s five forces analysis and market share analysis of high potency active pharmaceutical ingredient market provides detailed information on current competitive landscape of the global HPAPI market. Furthermore, market attractiveness analysis provides information on most attractive geographies for HPAPI manufacturing.

Finally, the report profiles major players in the global HPAPI market which include Alkermes plc, Cambrex Corporation, Dr. Reddy's Laboratories, Lonza Group, Novasep, Sandoz International GmbH, Pfizer, Inc., Sigma-Aldrich Co. LLC., WuXi AppTec. Each of the companies are profiled for parameters including: company overview, financial overview, product portfolio, business strategies and recent developments The report represents HPAPI market estimation and forecast in the form of 26 charts and figures, and 4 tables and comprises 85 slides.


 
 
Back To Top